Kadmon Holdings, Inc. is a biopharmaceutical company, which engages in discovering, developing, and commercializing small molecules and biologics. It focuses on the treatment of autoimmune, inflammatory, and fibrotic diseases. Its products include Ribasphere, RibaPak, Tetrabenazine, Valganciclovir, Abacavir, Entecavir, Lamivudine, and Zidovudine. The company was founded by Steven N. Gordon in September 2010 and is headquartered in New York, NY.
The short term market consensus for KDMN have change to Bullish
Our Proprietary Trading System indicates the following:
The Primary Trend (PT) given by the Global Monthly TIME BAR (GMTB) is currently Bullish
The Secondary Trend (ST), given by the Global Weekly TIME BAR (GWTB) is currently Bullish
The Medium Term Trend (MTT), given by the Global Daily TIME BAR (GDTB) is currently Bullish
The Short Term Trend (STT), given by the Global Four Hour TIME BAR (GFHTB) is currently Bullish
In light of the above trend analysis we have executed a bullish trade on KDMN using the following data:
Global Entry Signal For Trade #1: Buy @ $ 4.34
Global Trailing Stop Loss Trade #1: @ $2.92
Global Target Profit Trade #1 : @ $20.30
Global Trade Management Strategy: We applied the Global Trailing Stop System for Global Trading Strategy #6.
Trading is risky
There is a substantial risk of loss in futures and Forex trading. Online trading of stocks and options is extremely risky. Assume you will lose money. Don’t trade with money you cannot afford to lose.